All lobbying filings
CGCN GROUP, LLC
CGCN GROUP, LLC filed a Q3 report for FRESENIUS KABI USA, LLC on October 19, 2026, reporting $50,000 in lobbying income.
Lobbying for FRESENIUS KABI USA, LLC · Healthcare company
Filing · LD-2 quarterly report
Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 19, 2026
Income
$50,000
What the client paid this registrant for the period.
Client based in
Illinois
Government bodies contacted
5
Lobbying activity
4
Buy America legislation, tariffs, and tax incentives.
Section 232 investigation into pharmaceuticals and unfair trade practices.
U.S. manufacturing incentives.
Sec. 232 investigation on pharmaceutical sector, tariffs, Buy America policies, Most Favored Nations Executive Order, reciprocal tariffs, essential medicines drug shortages related to trade agreements.